Outcomes of percutaneous left atrial appendage occlusion device implantation in atrial fibrillation patients based on underlying stroke risk

被引:9
作者
Messele, Lydia Fekadu [1 ]
Khan, Muhammad Zia [2 ]
Darden, Douglas [3 ]
Agarwal, Siddharth [4 ]
Krishan, Satyam [4 ]
Pasupula, Deepak Kumar [5 ]
Asad, Zain Ul Abideen [4 ]
Balla, Sudarshan [2 ]
Singh, Gagan D. [1 ]
Srivatsa, Uma N. [1 ]
Munir, Muhammad Bilal [1 ]
机构
[1] Univ Calif Davis, Sch Med, Div Cardiovasc Med, Sect Cardiac Electrophysiol, 4860 & St Suite 2800, Sacramento, CA 95817 USA
[2] West Virginia Univ, Heart & Vasc Inst, Div Cardiovasc Med, Morgantown, WV USA
[3] Kansas City Heart Rhythm Inst, Div Cardiol, Overland Pk, KS USA
[4] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA
[5] MercyOne North Iowa Med Ctr, Div Cardiovasc Med, Mason City, IA USA
来源
EUROPACE | 2023年 / 25卷 / 04期
关键词
Left atrial appendage occlusion; Stroke risk; CHA(2)DS(2)-VASc score; Outcomes; Complications; CHA(2)DS(2)-VASC SCORE; CLOSURE;
D O I
10.1093/europace/euad049
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims To determine outcomes in atrial fibrillation patients undergoing percutaneous left atrial appendage occlusion (LAAO) based on the underlying stroke risk (defined by the CHA(2)DS(2)-VASc score). Methods and results Data were extracted from the National Inpatient Sample for calendar years 2016-20. Left atrial appendage occlusion implantations were identified on the basis of the International Classification of Diseases, 10th Revision, Clinical Modification code of 02L73DK. The study sample was stratified on the basis of the CHA(2)DS(2)-VASc score into three groups (scores of 3, 4, and >= 5). The outcomes assessed in our study included complications and resource utilization. A total of 73 795 LAAO device implantations were studied. Approximately 63% of LAAO device implantations occurred in patients with CHA(2)DS(2)-VASc scores of 4 and >= 5. The crude prevalence of pericardial effusion requiring intervention was higher with increased CHA(2)DS(2)-VASc score (1.4% in patients with a score of >= 5 vs. 1.1% in patients with a score of 4 vs. 0.8% in patients with a score of 3, P < 0.01). In the multivariable model adjusted for potential confounders, CHA(2)DS(2)-VASc scores of 4 and >= 5 were found to be independently associated with overall complications [adjusted odds ratio (aOR) 1.26, 95% confidence interval (CI) 1.18-1.35, and aOR 1.88, 95% CI 1.73-2.04, respectively] and prolonged length of stay (aOR 1.18, 95% CI 1.11-1.25, and aOR 1.54, 95% CI 1.44-1.66, respectively). Conclusion A higher CHA(2)DS(2)-VASc score was associated with an increased risk of peri-procedural complications and resource utilization after LAAO. These findings highlight the importance of patient selection for the LAAO procedure and need validation in future studies.
引用
收藏
页码:1415 / 1422
页数:8
相关论文
共 19 条
[1]  
Agency for Healthcare Research and Quality, OV NAT INP SAMPL NIS
[2]  
[Anonymous], CTR MEDICARE MEDICAI
[3]  
Centers for Medicare and Medicaid Services, PERC LEFT ATR APP LA
[4]   Comparative data on left atrial appendage occlusion efficacy and clinical outcomes by age group in theAmplatzer™ Amulet™ Occluder Observational Study [J].
Freixa, Xavier ;
Schmidt, Boris ;
Mazzone, Patrizio ;
Berti, Sergio ;
Fischer, Sven ;
Lund, Juha ;
Montorfano, Matteo ;
Della Bella, Paolo ;
Lam, Simon Cheung Chi ;
Cruz-Gonzalez, Ignacio ;
Gage, Ryan ;
Omran, Heyder ;
Tarantini, Giuseppe ;
Aminian, Adel ;
Nielsen-Kudsk, Jens Erik .
EUROPACE, 2021, 23 (02) :238-246
[5]   EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update [J].
Glikson, Michael ;
Wolff, Rafael ;
Hindricks, Gerhard ;
Mandrola, John ;
Camm, A. John ;
Lip, Gregory Y. H. ;
Fauchier, Laurent ;
Betts, Tim R. ;
Lewalter, Thorsten ;
Saw, Jacqueline ;
Tzikas, Apostolos ;
Sternik, Leonid ;
Nietlispach, Fabian ;
Berti, Sergio ;
Sievert, Horst ;
Bertog, Stefan ;
Meier, Bernhard .
EUROPACE, 2020, 22 (02) :184
[6]   Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial [J].
Holmes, David R. ;
Reddy, Vivek Y. ;
Turi, Zoltan G. ;
Doshi, Shephal K. ;
Sievert, Horst ;
Buchbinder, Maurice ;
Mullin, Christopher M. ;
Sick, Peter .
LANCET, 2009, 374 (9689) :534-542
[7]   Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy [J].
Holmes, David R., Jr. ;
Kar, Saibal ;
Price, Matthew J. ;
Whisenant, Brian ;
Sievert, Horst ;
Doshi, Shephal K. ;
Huber, Kenneth ;
Reddy, Vivek Y. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (01) :1-12
[8]  
January CT, 2019, CIRCULATION, V140, pE125, DOI [10.1161/CIR.0000000000000665, 10.1016/j.jacc.2019.01.011]
[9]   Utilization and procedural adverse outcomes associated with Watchman device implantation [J].
Khalil, Fouad ;
Arora, Shilpkumar ;
Killu, Ammar M. ;
Tripathi, Byomesh ;
DeSimone, Christopher, V ;
Egbe, Alexander ;
Noseworthy, Peter A. ;
Kapa, Suraj ;
Mulpuru, Siva ;
Gersh, Bernard ;
Mohamad, Alkhouli ;
Friedman, Paul ;
Holmes, David ;
Deshmukh, Abhishek J. .
EUROPACE, 2021, 23 (02) :247-253
[10]   Racial Disparities in In-Hospital Adverse Events Among Patients With Atrial Fibrillation Implanted With a Watchman Left Atrial Appendage Occlusion Device A US National Perspective [J].
Khan, Muhammad Zia ;
Munir, Muhammad Bilal ;
Darden, Douglas ;
Pasupula, Deepak Kumar ;
Balla, Sudarshan ;
Han, Frederick T. ;
Reeves, Ryan ;
Hsu, Jonathan C. .
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2021, 14 (05) :504-512